Drug Profile
Research programme: microbial therapeutics - Vedanta Biosciences
Alternative Names: Microbiome-based therapeutics - VedantaLatest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Vedanta Biosciences
- Developer Keio University School of Medicine; Vedanta Biosciences
- Class Anti-infectives; Anti-inflammatories; Bacteria; Immunotherapies
- Mechanism of Action Helper-inducer T-lymphocyte stimulants; Immunomodulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Graft-versus-host disease; Infections; Inflammatory bowel diseases
Most Recent Events
- 28 Nov 2023 Vedanta Biosciences has patent protection for cover compositions of clostridia bacterial species in European Union
- 28 Aug 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 28 Jul 2022 No recent reports of development identified for preclinical development in Graft-versus-host-disease in USA